Related Experiment Video
Updated: Sep 4, 2025

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
Published on: August 1, 2025
Cannabinoids and solid organ transplantation: Psychiatric perspectives and recommendations
Gerald Scott Winder1, Sarah R Andrews2, Arpita Goswami Banerjee3
1University of Michigan Department of Psychiatry, Ann Arbor, Michigan, USA.
Cannabinoid use in solid organ transplantation (SOT) patients presents challenges due to limited research and inconsistent guidelines. This review synthesizes current knowledge to aid clinicians in managing these complex cases.
Area of Science:
- Transplantation Medicine
- Cannabinoid Research
- Clinical Practice Guidelines
Background:
- Cannabinoid use in solid organ transplantation (SOT) patients is a complex issue with inconsistent clinical approaches.
- Existing scientific literature on cannabinoids in SOT is limited, primarily focusing on liver and kidney transplants.
- Professional society recommendations offer a mix of specific and vague guidance, reflecting the ongoing dilemma.
Purpose of the Study:
- To systematically review existing studies on clinician perceptions, use rates, and clinical impact of cannabinoid use in SOT patients.
- To collate professional society guidance and synthesize diverse medical literature on cannabinoid use in psychiatry and addiction relevant to transplantation.
- To provide clinical and policy recommendations and identify future research areas regarding cannabinoid use in SOT.
Main Methods:
- Systematized review of studies on clinician perceptions, use rates, and clinical impact of cannabinoid use in SOT patients.
- Collation of professional society guidance on cannabinoid use in transplantation.
- Synthesis of diverse medical literature on psychiatric and addiction aspects of cannabinoid use pertinent to SOT clinicians.
Main Results:
- Limited existing studies on clinician perceptions, use rates, and clinical impact of cannabinoid use in SOT patients.
- Professional society guidance is variable, lacking comprehensive recommendations.
- SOT teams may lack adequate staffing or training to manage neuropsychiatric cannabinoid effects and risks.
Conclusions:
- Cannabinoid use in SOT patients requires a comprehensive, interprofessional approach due to multifaceted challenges.
- Further research and standardized guidelines are needed to address clinician uncertainty and improve patient care.
- SOT teams need enhanced training to manage the neuropsychiatric effects and risks associated with cannabinoid use.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Hallucinogens and Psychedelics
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...

